1.75
+0.1(+6.06%)
Currency In USD
| Previous Close | 1.65 |
| Open | 1.82 |
| Day High | 1.85 |
| Day Low | 1.7 |
| 52-Week High | 3.32 |
| 52-Week Low | 1.33 |
| Volume | 860,038 |
| Average Volume | 430,629 |
| Market Cap | 124.26M |
| PE | 3.72 |
| EPS | 0.47 |
| Moving Average 50 Days | 1.64 |
| Moving Average 200 Days | 1.76 |
| Change | 0.1 |
If you invested $1000 in Inhibikase Therapeutics, Inc. (IKT) since IPO date, it would be worth $29.46 as of January 22, 2026 at a share price of $1.75. Whereas If you bought $1000 worth of Inhibikase Therapeutics, Inc. (IKT) shares 5 years ago, it would be worth $44.19 as of January 22, 2026 at a share price of $1.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Nov 21, 2025 2:54 AM GMT
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“P
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Nov 20, 2025 9:12 PM GMT
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
GlobeNewswire Inc.
Nov 20, 2025 9:01 PM GMT
Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibik